Summit Investment Advisors Inc. Has $474,000 Stock Position in Cencora, Inc. $COR

Summit Investment Advisors Inc. reduced its position in Cencora, Inc. (NYSE:COR) by 8.6% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,704 shares of the company’s stock after selling 160 shares during the quarter. Summit Investment Advisors Inc.’s holdings in Cencora were worth $474,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Cencora by 7.2% in the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after buying an additional 363,402 shares during the period. Boston Partners grew its holdings in shares of Cencora by 8.1% during the first quarter. Boston Partners now owns 5,411,193 shares of the company’s stock valued at $1,505,984,000 after buying an additional 404,093 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after buying an additional 1,364,433 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Cencora by 9.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock valued at $475,890,000 after buying an additional 154,311 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on COR shares. UBS Group raised their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. TD Cowen increased their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Finally, Mizuho lifted their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average target price of $371.09.

Cencora Stock Up 0.5%

COR opened at $365.06 on Friday. The firm has a market cap of $70.78 billion, a P/E ratio of 37.56, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The business has a 50 day moving average price of $319.97 and a 200 day moving average price of $301.57. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $366.17.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the firm posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.